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circulating miRNAs panels was performed to estimate their predictive
value on the components. After which, individual correlation between
predicting genes and miRNAs per component was performed.
Results: To characterize the expression level and pattern of selected
senescence genes (162 senescence genes), we performed in silico look
up of a previously assessed RNA sequencing dataset of preserved (n¼57)
and lesioned (n¼44) OA. From the total dataset of 162 genes (n¼101),
137 genes were expressed in OA preserved and lesioned cartilage and
were considered for further analysis. To investigate different senescence processes active in preserved OA cartilage, we performed a PCA
analysis on the 137 senescence genes in cartilage (n¼57) which identiﬁed 4 unique component, retaining 71% of the total variation,
reﬂecting different networks of correlating senescence genes or subtypes. Pathway analysis with DAVID revealed NF-kappa Beta signalling
pathway as the most signiﬁcant (FDR 6.95E-07) and unique pathway of
component 1 (Senescence subtype 1). In component 2 (senescence
subtype 2), angiogenesis/VEGF pathway revealed to be important (FDR
1.21E-02 and 2.17E-02 respectively) with the involvement of VEGFA.
These results suggest that different senescence processes are active in
preserved OA cartilage such as NF-kappa beta in senescence subtype 1
and angiogenesis/VEGF pathways in senescence subtype 2. To identify
gene expression patterns efﬁciently marking the active senescence
subtypes we performed LASSO analyses. In total 23 and 28 genes were
retained for subtype 1 and 2 respectively. In subtype 1, PLAUR had the
highest positive effect with LASSO coefﬁcient (beta, b) of 0.13. Moreover,
other notable genes that marked senescent subtype 1 were CDKN1A and
MMP13 representing, respectively, both general and speciﬁc senescence
processes. To identify non-invasive blood biomarkers for identiﬁed
senescence subtypes, an overlapping plasma miRNA RNA sequencing
dataset (n¼21) was explored. LASSO analyses identiﬁed a panel of 4
circulating miRNAs marking subtype 1 speciﬁc active senescence processes. As can be seen in Figure 1A, these circulating miRNAs had a
predicting value (area under the curve) of >0.80 reﬂecting the capability
of the model to correctly classify cases in senescence subtype 1 with
>80% chance, indicating clinical relevant predictive capabilities. Notably, individual miRNA’s from this panel showed strong positive correlation to e.g. MMP13 (r¼0.68, Figure 1B).
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BLOOD MICRO-RNAS DELINEATING SENESCENCE PHENOTYPES IN
OSTEOARTHRITIS
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Purpose: The rapid increase of aged individuals is associated with a
concomitant increase in chronic diseases, such as osteoarthritis (OA). A
hallmark of such age-related degenerative diseases is the heterogeneous accumulation of senescent cells (SCs) affecting tissues by virtue
of a well-deﬁned senescence-associated secretory phenotype (SASP). In
this regard, cellular senescence was shown to be a bona ﬁde driver of OA
in all stages in mice. Identiﬁcation of non-invasive reliable biomarkers
that sensitively reﬂect cellular senescence in human articular cartilage
is essential to allow efﬁcient monitoring and to evaluate therapy efﬁcacy with e.g. senolytics. In the current study, we set out to characterize
heterogeneity of cellular senescence within preserved osteoarthritis
(OA) cartilage while identifying blood-biomarkers in the form of
microRNAs (miRNAs).
Methods: By applying a literature search, 162 senescence genes were
selected for in silico analyses in a previously assessed RNA sequencing
dataset of 57 macroscopically preserved and 44 lesioned cartilage
samples of the RAAK study. To reduce dimension of the transcriptomics
senescence data, principal components analysis (PCA) was performed
(genes were retained with a correlation j>0.4j to each component).
Afterwards, Least Absolute Shrinkage Selector Operator (LASSO) analysis was applied with 5-fold validation to identify predicting genes per
component. 399 circulating miRNA’s of previously assessed miRNA-seq
dataset of blood plasma (n¼21 preserved OA samples overlapping with
mRNA-seq cartilage dataset) were correlated to the components. After
pre-selection, a panel of predicting circulating miRNAs was selected per
component using LASSO analysis. Receiving operating curves (ROC) of

Conclusions: By exploring a mRNA dataset of cartilage, we identiﬁed 4
different components reﬂecting heterogeneous senescence processes in
preserved cartilage of OA patients. By subsequently integrating a miRNA
dataset of blood plasma, potential new blood biomarkers in the form of
miRNAs were identiﬁed marking senescence component 1 with high
reliability. To be able to translate this further into the clinic, validation of
the results is necessary. Together, these data contribute to a better
understanding of the heterogeneity of the OA pathophysiology with the
further development of diagnostic biomarkers to further advance the
OA diagnostics.

(A) ROC curve of baseline characteristic with a panel of 4 miRNAs (black)
and a reference line (grey), showing an area under the curve of >0.8. (B)
Scatterplot of normalized expression counts of a representative individual
cartilage gene (MMP13) and circulating miRNA of senescence subtype 1,
showing correlation of 0.68.
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Purpose: There is an outstanding need to identify minimally invasive
biomarkers for reliable detection of knee osteoarthritis (OA). Current
clinical diagnostic methods are limited since OA symptoms do not
always correlate with structural degeneration in the joint. Soluble
biochemical markers provide a better readout of disease activity, and a
variety of blood, synovial ﬂuid, and urine biomarkers have been
explored in OA, including microRNAs. As small, non-coding RNAs,
microRNAs are promising biomarker candidates since they are easy to
detect in bioﬂuids, are relatively stable (i.e. resistant to enzymatic
degradation), and can be reliably quantiﬁed such that levels can be
linked to disease. Furthermore, microRNAs are known drivers of OA
pathology, and their expression may precede joint degeneration, when
opportunities for intervention still exist. Based on this, circulating
microRNAs have strong potential to serve as biomarkers for knee OA,
but a major limitation is lack of reproducibility across studies proﬁling
circulating microRNAs in OA. While sequencing is the gold standard
method for unbiased proﬁling of microRNAs, there are critical experimental design and analysis parameters that can impact the results. The
objectives of this study are to identify circulating microRNAs in latestage radiographic knee OA compared to non-OA controls using existing
microRNA-sequencing data, and to validate the ﬁndings using our
recently established Henry Ford Health System (HFHS) Osteoarthritis
cohort.
Methods: We searched the literature for microRNA-sequencing studies
proﬁling circulating microRNAs in OA versus non-OA participants and
identiﬁed two studies, one conducted in Norway (Aae et al., 2020) and
the other in France (Rousseau et al., 2020). We obtained raw sequencing
data from the authors and re-analyzed the data by applying our recently
reported method for microRNA-sequencing analysis. Among other
changes (e.g. normalization method), we re-deﬁned the cohorts to
include participants with only Kellgren-Lawrence (KL) grades 3 and 4 in
the OA group (compared to KL 0 to 4 and total knee arthroplasty in the
original Norway study and KL 2 and 3 in the original France study) and
with KL grade 0 in the non-OA group (consistent with the original
Norway study and compared to KL 0 and 1 in the original France study).
Following differential expression analysis using a multivariate model
adjusted for age, sex, and body mass index, we prioritized microRNAs
that were common to the OA groups in both cohorts. We next performed validation by real-time PCR in the HFHS Osteoarthritis cohort
utilizing plasma samples from participants with unilateral and/or
bilateral knee and/or hip OA and non-OA controls.
Results: As reported by the two original microRNA-sequencing studies,
there were no signiﬁcant differences in the Norway cohort and 3 differentially expressed microRNAs in OA (miR-139-5p, miR-1299, miR200a-3p) in the France cohort, though none achieved validation in realtime PCR experiments. Following our re-analysis, we identiﬁed 23 and
82 differentially expressed microRNAs (p<0.1) in the Norway and
France cohorts, respectively, with 3 microRNAs in common between the
OA groups: miR-126-3p, miR-30c-2-3p, and miR-144-5p. Of these, miR126-3p had the highest counts-per-million in both cohorts, showed an
increased fold change in OA in both cohorts (p<0.05; Figure 1A and 1B),
and was found in 100% and 91% of OA samples and 0% and 35% of nonOA samples in the Norway and France cohorts, respectively. Furthermore, a report in 2014 by Borgonio Cuadra et al. identiﬁed circulating miR-126 to be elevated in OA (KL 2 and 3) compared to non-OA
(KL 0) by both real-time PCR array and real-time PCR validation
experiments (Figure 1C). This led us to explore miR-126-3p expression
in plasma samples from the HFHS Osteoarthritis cohort where we found
a consistent increase in knee OA (symptomatic, KL 3 or 4), irrespective
of unilateral or bilateral, compared to non-OA controls (asymptomatic,
KL 0), yet no signiﬁcant increase in hip OA (Figure 1D).
Conclusions: Through application of our microRNA-sequencing analysis method, we identiﬁed circulating miR-126-3p to be increased in
late-stage radiographic knee OA compared to non-OA controls in two
studies originally reporting no validated differences. This ﬁnding is
supported by previous literature identifying circulating miR-126 to be
elevated in knee OA compared to non-OA controls and is extended by
our data showing that the increase may be unique to knee OA and not
hip OA. Taken together, there are now data from four independent
cohorts demonstrating an increase in circulating miR-126-3p in knee
OA, suggesting that this microRNA may have utility as a biomarker for
OA.
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Med. Ctr., Boston, MA; 3 Dept. of Hlth.Sci., Sargent Coll. of Hlth.and
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Med. and Epidemiology, Dept. of Med., Boston Univ. Sch. of Med., Boston,
MA; 5 Div. of Cardiovascular Med., Beth Israel Deaconess Med. Ctr.,
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Purpose: Osteoarthritis (OA) at the knees and hands may not share the
same etiology. For example, pathogenesis of large joint OA like knee OA
may be determined in large part by mechanopathology, while hand OA
has been long considered the consequence of metabolic or systemic
inﬂuences. Identifying shared aspects of disease across different joint
sites may provide insights into relevant pathways that may be commonly targeted across different OA joint sites. We aimed to determine
whether there are proteins associated with both knee and hand OA and
whether these proteins are associated with disease incidence and
prevalence.
Methods: We analyzed data from the Framingham Heart Offspring
study, a longitudinal community-based study that began in 1971 with
the recruitment of 5,124 individuals who were children of the Original
Study cohort and their spouses. Of the 3,236 participants who had a
visit in 1991-1995 and had available plasma samples, 1,913 individuals
had proteomic proﬁling using the SOMAscan platform (version 1.1,
which contained 1,129 aptamers or version 1.3, which contained 1,305
aptamers). In each batch, age and sex-adjusted protein values were log
transformed and standardized to a mean ¼ 0 and standard deviation
(SD) ¼ 1. The median intra-assay CV was < 4% and median inter-assay
CV was < 7% across batches. A subset of 625-636 Offspring study participants had x-ray imaging of the hands and knees, respectively, in
1991-1995 (mean age ¼ 55 years, range ¼ 32-79 years, 57% women) and
again in 2002-2005 (~9.5 years later). We deﬁned prevalent OA when a
person had radiographic OA of KL grade >¼2 in at least one joint in knee
or hand at the initial exam in 1991-1995. We then excluded persons
with prevalent OA in the target joints and deﬁned incident disease as
the new development of radiographic OA grade >¼2 in 2002-2005. We
conducted logistic regression adjusted for age, sex, and technical
covariates to identify proteins associated with the odds of prevalent
hand and/or knee OA in 1991-1995 (P-value < 0.05). We then assessed
whether the identiﬁed proteins were also associated with the odds of
incident hand and/or knee OA in 2002-2005 (P-value < 0.05).
Results: We identiﬁed 103 plasma proteins associated with knee OA (57
positive and 46 negative) and 52 plasma proteins associated with hand
OA (32 positive and 20 negative) at the baseline visit in 1991-1995. Of
these proteins, 10 plasma proteins were also associated with incident
knee OA and 8 plasma proteins were also associated with incident hand
OA at the follow-up visit in 2002-2005 (P-value < 0.05) (Table 1). We
identiﬁed two proteins that were signiﬁcantly associated with both
prevalent and incident hand and knee OA, showing consistency of
effects in both the knees and hands: Factor I, which regulates complement activation, and IGFBP-1, an insulin-like growth factor-binding
protein, known to inﬂuence cartilage metabolism. Given the exploratory nature of our study and small sample, we report here nominal
ﬁndings. One protein achieved an FDR < 0.05, IL-17D, which was
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